Precigen, Inc.
PGEN Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$6.04
KIRA · Stoqly’s AI analyst, in plain words
- Precigen, Inc. had $9.7M of revenue in fiscal 2025, up 146.7% on the year before. Over five years, revenue changed −21.3% a year on average.
- Its operating margin was −1,141.1%, up 2,299.1 pts: of every 100 in sales, about −1,141 is left after running the business.
- Precigen, Inc. lost $251M in fiscal 2025.
- Free cash flow was −$89.8M in fiscal 2025, −927.6% of revenue.
- Precigen, Inc. has $4.7M more cash than debt.
Market cap
$2.5B
P/E
—
Revenue
$9.7M
Net income
−$251M
Free cash flow
−$89.8M
Operating margin
−1,141.1%
Precigen, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+146.7%
Yes. Sales grew 146.7% last year.
Does it make a profit?
−2,588.2%
No. It lost money last year.
Does profit turn into cash?
−927.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Precigen, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- PRECIGEN, INC.
- CIK
- 0001356090
Precigen, Inc. · PGEN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M |
| Revenue growth | −55.4% | 88.6% | −76.9% | −36.9% | 146.7% |
| Operating margin | — | — | −1,602.5% | −3,440.2% | −1,141.1% |
| Net income | −$92.2M | $28.3M | −$95.9M | −$126M | −$251M |
| Net margin | −646.0% | 105.2% | −1,540.6% | −3,216.2% | −2,588.2% |
| Diluted EPS | −$0.47 | $0.14 | −$0.39 | −$0.47 | −$1.37 |
| Cash | |||||
| Cash from operations | −$55.8M | −$65.0M | −$66.9M | −$68.2M | −$87.8M |
| Capital expenditure | $7.2M | $4.9M | $1.5M | $8.6M | $2.0M |
| Free cash flow | −$63.0M | −$70.0M | −$68.5M | −$76.8M | −$89.8M |
| FCF margin | −441.7% | −260.0% | −1,099.9% | −1,955.6% | −927.6% |
| Share count change | 18.4% | 1.3% | 22.0% | 9.5% | 16.9% |
| Debt and strength | |||||
| Cash and short-term investments | $109M | $56.0M | $62.9M | $97.9M | $97.9M |
| Debt incl. finance leases | $180M | $86.4M | $0.0M | $0.0M | $93.2M |
| Shareholders' equity | $107M | $126M | $118M | $38.5M | $20.9M |
| Current ratio | 4.5x | 1.5x | 3.0x | 4.8x | 3.1x |
| Interest coverage | — | — | −213.2x | −22,504.8x | −28.6x |
| Returns and quality | |||||
| Return on capital | — | — | −141.6% | — | −538.0% |
| Return on equity | −105.6% | 24.2% | −78.4% | −160.8% | −843.6% |
| Return on tangible equity | −526.6% | 63.1% | −187.4% | −846.1% | −17,206.3% |
| Piotroski F-score | 4 | 4 | 3 | 2 | 2 |
| Altman Z'' | — | — | −41.0 | −49.0 | −50.4 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$44.6M
7 insiders
Of sales under plans
12%
$5.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Precigen, Inc. · PGEN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.04 a share, the company is worth $2.5B.
Source: SEC EDGAR XBRL filings (CIK 0001356090). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.